For the quarter ending 2025-09-30, DWTX made $15,888,271 in revenue. -$15,744,616 in net income. Net profit margin of -99.10%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 14,521,342 | 2,569,943 | ||
| General and administrative expenses | 1,287,783 | 1,353,172 | ||
| Total operating expenses | 15,809,125 | 3,923,115 | ||
| Loss from operations | -15,809,125 | -3,923,115 | ||
| Interest income, net | 80,582 | 111,379 | ||
| Exchange loss, net | -17,509 | 4,532 | ||
| Total other income (expense) | 63,073 | 115,911 | ||
| Loss before income taxes | -15,746,052 | -3,807,204 | ||
| Deferred income tax benefit (expense) | -1,436 | 149 | ||
| Net loss | -15,744,616 | -3,807,353 | ||
| Net loss attributable to common stockholders | -15,744,616 | -3,807,353 | ||
| Earnings per share, basic | -8.2 | -1.99 | ||
| Earnings per share, diluted | -8.2 | -1.99 | ||
| Weighted average number of shares outstanding, basic | 1,919,433 | 1,911,128 | ||
| Weighted average number of shares outstanding, diluted | 1,919,433 | 1,911,128 | ||
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)